There's just one myelofibrosis treatment at the moment, Jakafi from Incyte (NASDAQ: INCY). Sales of Incyte's drug are expected to reach $1.7 billion in 2019, and CPI-0601 sales could peak at more than $1 billion annually if it continues to produce results in line with those we've already seen. The Motley Fool recommends Amgen and Incyte.